Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449627 | 0.90 | ADORA2A (0.61) | ADORA2AADORA1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1449821 | 0.90 | ADORA2A (0.59) | ADORA2AADORA1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1449374 | 0.87 | ADORA2A (0.91) | ADORA2AADORA1KDM4EMEN1KMT2A | |
| SCHEMBL1449367 | 0.86 | ADORA2A (0.83) | ADORA2AADORA1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1449994 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1MEN1KMT2AALDH1A1 | |
| Cyclopropane SCHEMBL15484716 | 0.85 | ADORA2A (0.79) | ADORA2AADORA1SMN1; SMN2KDM4EALDH1A1 | |
| Cyclohexane SCHEMBL15484642 | 0.85 | ADORA2A (0.79) | ADORA2AADORA1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5508760 | 0.83 | ADORA2A (0.82) | ADORA2AADORA1KDM4EMEN1KMT2A | |
| SCHEMBL1449376 | 0.81 | ADORA2A (0.77) | ADORA2AADORA1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1450057 | 0.81 | ADORA2A (0.70) | ADORA2AADORA1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| CN-101061115-A | 2-acylaminothiazole derivatives | LUNDBECK & CO AS H (DK) | 2007-10-24 | — | — | CN | claimed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| CN-101061115-A | 2-acylaminothiazole derivatives | LUNDBECK & CO AS H (DK) | 2007-10-24 | — | — | CN | disclosed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885SMN1; SMN2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.